Lantheus Holdings, Inc
LNTH
$83.94
+1.45%
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company operating in the specialty and generic drug manufacturing sector. It is a key player in enabling clinicians to find, fight, and follow disease, with a core business built around radiopharmaceutical oncology and precision diagnostics.…
LNTH
Lantheus Holdings, Inc
$83.94
Investment Opinion: Should I buy LNTH Today?
Based on a synthesis of the financial, valuation, and market data, the objective assessment for LNTH is a Hold. The company's impressive profitability turnaround, strong balance sheet, and operational efficiency are clear positives. However, these are counterbalanced by premium valuation metrics, only modest revenue growth, and high short interest suggesting skepticism. The stock appears to be fairly valued at current levels, pricing in the recent operational improvements but leaving limited margin for error. Investors may want to wait for a more attractive entry point or clearer signs of accelerating top-line growth before establishing a new position.
Sign up to view all
LNTH 12-Month Price Forecast
The analysis yields a neutral stance. The fundamental improvement is undeniable, but the stock's significant run-up and current valuation appear to largely reflect this positive shift. The risk/reward profile seems balanced over the next 12 months, with outcomes heavily dependent on the trajectory of revenue growth.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Lantheus Holdings, Inc's 12-month outlook, with a consensus price target around $109.12 and implied upside of +30.0% versus the current price.
Average Target
$109.12
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$67 - $109
Analyst target range
No sufficient analyst coverage available. The provided data includes recent rating actions from four different firms, but does not contain consensus target prices or a detailed ratings distribution. Recent actions include a mix of 'Buy', 'Hold', 'Market Outperform', and 'Outperform' ratings.
Bulls vs Bears: LNTH Investment Factors
Lantheus presents a compelling story of financial improvement, with a strong shift to profitability and a fortress balance sheet. However, this is tempered by modest top-line growth, high valuation multiples, and notable stock price volatility. The investment case hinges on whether earnings growth can accelerate to justify the current valuation.
Bullish
- Strong Profitability Turnaround: Swung to net income of $54.1M in Q4 2025 from a loss, with net margin of 13.3%.
- Robust Balance Sheet & Cash Flow: Minimal debt (D/E 0.0007), strong current ratio (2.70), and healthy FCF of $348.6M TTM.
- Attractive Forward Valuation: Forward P/E of 12.05 suggests expectations for earnings growth from current levels.
- Recent Market Outperformance: Up 44% over 6 months, significantly outperforming the S&P 500's decline.
Bearish
- Modest Revenue Growth: Q4 2025 revenue grew only 4.0% YoY, indicating potential market saturation.
- High Valuation Multiples: Trailing P/E of 19.23 and P/B of 4.12 are elevated relative to some peers.
- Significant Price Volatility: Stock trades 30% below 52-week high, with a negative beta suggesting unstable correlation.
- High Short Interest: Short ratio of 4.71 indicates significant bearish sentiment from some investors.
LNTH Technical Analysis
The stock has demonstrated a strong overall uptrend over the past six months, rising 44.0% from its price on October 2, 2025. It has significantly outperformed the broader market, with a 6-month relative strength of 46.8 against the S&P 500's decline of 2.8%. In the short term, the stock has been volatile but positive, gaining 13.97% over the last three months and 1.25% over the past month. This contrasts with the S&P 500's declines of 4.63% and 5.25% over the same periods, respectively, highlighting its recent market leadership. The current price of $75.85 is positioned approximately 30% above its 52-week low of $47.25 but remains about 30% below its 52-week high of $108.91. The stock's beta of -0.14 indicates it has moved inversely to the market during the measured period.
Beta
-0.13
-0.13x market volatility
Max Drawdown
-53.9%
Largest decline past year
52-Week Range
$47-$109
Price range past year
Annual Return
-18.3%
Cumulative gain past year
| Period | LNTH Return | S&P 500 |
|---|---|---|
| 1m | +6.9% | +4.6% |
| 3m | +28.3% | +1.1% |
| 6m | +51.0% | +5.3% |
| 1y | -18.3% | +30.2% |
| ytd | +24.8% | +2.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LNTH Fundamental Analysis
Revenue growth has been modest but positive, with Q4 2025 revenue of $406.8 million representing a 4.0% year-over-year increase. Profitability has improved significantly, as the company swung from a net loss of $11.8 million in Q4 2024 to a net income of $54.1 million in Q4 2025, with the net margin expanding to 13.3%. The company maintains a very strong balance sheet with minimal leverage, evidenced by a debt-to-equity ratio of just 0.0007 and a robust current ratio of 2.70. Cash flow generation is healthy, with trailing twelve-month free cash flow of $348.6 million. Operational efficiency metrics are solid, with a return on equity (ROE) of 21.43% and a return on assets (ROA) of 9.28%. The gross margin for the latest quarter was 59.21%, indicating good control over production costs.
Quarterly Revenue
$406786000.0B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.59%
Latest Quarter
Free Cash Flow
$348639000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LNTH Overvalued?
Given the company's positive net income, the primary valuation metric is the trailing P/E ratio, which stands at 19.23. The forward P/E is lower at 12.05, suggesting expectations of earnings growth. The price-to-sales ratio is 2.91, and the enterprise value to EBITDA is 10.24. Peer comparison data for industry averages is not available in the provided inputs. Therefore, a direct comparison to sector norms cannot be made at this time.
PE
19.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -498x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.2x
Enterprise Value Multiple
Investment Risk Disclosure
The primary financial risk is the company's modest revenue growth of 4.0% YoY, which may not support its elevated valuation multiples (P/E 19.23, P/B 4.12) if it persists. Market risks are pronounced, evidenced by high short interest (ratio 4.71) and significant price volatility; the stock remains 30% below its 52-week high despite a recent rally. The negative beta of -0.14 indicates an atypical, inverse relationship with the broader market, which could lead to unexpected performance during market shifts. Furthermore, the company operates in the competitive and regulatory-intensive radiopharmaceutical sector, where pipeline setbacks or reimbursement changes could impact future growth. The lack of a dividend also concentrates total return on capital appreciation, increasing dependence on stock performance.
FAQ
Key risks include: 1) Growth Risk: Modest 4.0% YoY revenue growth may not support high valuation multiples. 2) Valuation Risk: Elevated P/E and P/B ratios make the stock sensitive to earnings misses. 3) Market Risk: High short interest (ratio 4.71) and significant volatility, with the stock still 30% below its 52-week high. 4) Sector Risk: Exposure to regulatory and reimbursement pressures in the healthcare sector.
The 12-month outlook presents a range of scenarios. The base case (50% probability) sees the stock trading between $70 and $90, supported by current execution. The bull case (30%) targets $95 to $110 on accelerated growth. The bear case (20%) could see a decline to $47 to $65 if growth stalls and valuation multiples contract. The overall stance is neutral, with the path dependent heavily on future revenue growth figures.
LNTH appears fairly valued to slightly overvalued based on current metrics. Its trailing P/E of 19.23 and price-to-sales of 2.91 are not cheap, especially considering modest revenue growth. The lower forward P/E of 12.05 implies expected earnings growth, which justifies some premium. However, the negative PEG ratio and high P/B ratio of 4.12 suggest the market has already priced in significant future improvement.
Based on current data, LNTH is assessed as a Hold. The company's strong profitability (13.3% net margin) and balance sheet (minimal debt) are positives, but the stock's valuation appears full after a 44% six-month rally. The forward P/E of 12.05 suggests growth is expected, but with revenue growth at only 4.0%, new investors may want to wait for a better entry point or clearer growth acceleration.
LNTH is more suitable for a long-term investment horizon. The company's strong operational metrics (ROE 21.43%) and positioning in radiopharmaceuticals support a multi-year growth story. However, short-term volatility is high (negative beta of -0.14), and the stock may experience significant swings. Investors should be prepared to hold through periods of volatility to capture the potential benefits of the company's financial strength and market position.